Further benefits by early start of HIV treatment in low income countries: Survival estimates of early versus deferred antiretroviral therapy

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Johansson, Kjell A ^a   Robberstad, Bjarne ^a   Norheim, Ole F ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRY; EARLY INTERVENTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL TIME; TANZANIA;

EID: 77649313940     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-7-3     Document Type: Article

References (43)

1. Ho DD. Time to Hit HIV, Early and Hard. N Engl J Med 1995, 333:450-451. 10.1056/NEJM199508173330710, 7616996.
2. Yeni PG, Hammer SM, Hirsch MS, Saag MS, Schechter M, Carpenter CC, Fischl MA, Gatell JM, Gazzard BG, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Schooley RT, Thompson MA, Vella S, Volberding PA. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004, 292:251-265. 10.1001/jama.292.2.251, 15249575.
3. World Health Organisation Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. 2009, World Health Organisation.
4. Raizes E, Lindegren M, Ellerbrock T, Ferris R, Marston B. A Comparison of the Adult National Antiretroviral Therapy (ART) Guidelines of 15 PEPFAR Focus Countries. 2008,
5. Sabin CA, Phillips AN. Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?. Curr Opin Infect Dis 2009, 22:191-197. 10.1097/QCO.0b013e328326cd34, 19283914.
6. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, et al. Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. N Engl J Med 2009, 360:1815-1826. 10.1056/NEJMoa0807252, 19339714.
7. Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes . 2009, , http://www.nih.gov/news/health/jun2009/niaid-08a.htm
8. UNAIDS AIDS epidemic update. 2008, UNAIDS.
9. Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M, . Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. The lancet 2006, 367:817-824. Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups.
10. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:1897-1908. 10.1097/QAD.0b013e32830007cd, 18784453.
11. Lawn SD, Myer LL, Orrell CC, Bekker LG, Wood RR. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005, 19:2141-2148. 10.1097/01.aids.0000194802.89540.e1, 16284464.
12. Stringer JSA, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M. Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in Zambia: Feasibility and Early Outcomes. JAMA 2006, 296:782-793. 10.1001/jama.296.7.782, 16905784.
13. Etard J, Ndiaye I, Thierry-Mieg M, Guèye N, Guèye P, Lanièce I, Dieng A, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006, 12:1181-1189.
14. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. The Lancet 2006, 367:1335-1342.
15. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, Abo Y, Salamon R, Bissagnene E, Seyler C, Eholié S, Anglaret X. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007, 30:2483-2491.
16. McGrath N, Kranzer K, Saul J, Crampin AC, Malema S, Kachiwanda L, Zaba B, Jahn A, Fine PE, Glynn JR. Estimating the need for antiretroviral treatment and an assessment of a simplified HIV/AIDS case definition in rural Malawi. AIDS 2007, 21(Suppl 6):S105-113. 10.1097/01.aids.0000299417.69432.65, 18032933.
17. Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007, 46:91-100.
18. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E, . for the CII When to Start Antiretroviral Therapy in Resource-Limited Settings. Ann Intern Med 2009, 151:157-166. for the CII.
19. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Cote d'Ivoire. N Engl J Med 2006, 355:1141-1153. 10.1056/NEJMsa060247, 16971720.
20. Walensky R, Weinstein M, Yazdanpanah Y, Losina E, Mercincavage L, Touré S, Divi N, Anglaret X, Goldie S, Freedberg K. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS 2007, 11:973-982.
21. Cleary SM, McIntyre D, Boulle AM. The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis. Cost Eff Resour Alloc 2006, 4:20. 10.1186/1478-7547-4-20, 1770938, 17147833.
22. Bachmann M. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. AIDS care 2006, 18:109-120. 10.1080/09540120500159334, 16338768.
23. The eligibility for A. R. T. in lower income countries collaboration Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect 2008, 84:i31-36. 10.1136/sti.2008.029793, 2569418, 18647863, The eligibility for A. R. T. in lower income countries collaboration.
24. World Health Organisation 2009, World Health Organisation., http://www.who.int/whosis/database/life_tables/life_tables.cfm
25. Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), Tanzania National Bureau of Statistics, Macro International Inc Tanzania HIV/AIDS and Malaria Indicator Survey 2007-08. 2008, Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), Tanzania National Bureau of Statistics, Macro International Inc.
26. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009, 23:335-342. 10.1097/QAD.0b013e328321823f, 19114870.
27. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. Aids 2004, 18:1159-1168. 10.1097/00002030-200405210-00009, 15166531.
28. Badri M, Lawn SD, Wood R. Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006, 368:1254-1259. 10.1016/S0140-6736(06)69117-4, 17027731.
29. Pathipvanich P, Ariyoshi K, Rojanawiwat A, Wongchoosie S, Yingseree P, Yoshiike K, Warachit P, Sawanpanyalert P. Survival benefit from non-highly active antiretroviral therapy in a resource-constrained setting. Journal of acquired immune deficiency syndromes 2003, 32:157-160.
30. Costello C, Nelson KE, Suriyanon V, Sennun S, Tovanabutra S, Heilig CM, Shiboski S, Jamieson DJ, Robison V, Rungruenthanakit K, Duerr A. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol 2005, 34:577-584. 10.1093/ije/dyi023, 15737969.
31. French NN, Mujugira AA, Nakiyingi JJ, Mulder DD, Janoff EEN, Gilks CCF. Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease. Journal of acquired immune deficiency syndromes 1999, 22:509-516.
32. Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, Alabi A, Bayang A, Ariyoshi K, Whittle HC. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 2002, 16:1775-1783. 10.1097/00002030-200209060-00010, 12218389.
33. Laurent C, Ngom Gueye N, Ndour C, Gueye P, Diouf M, Diakhaté N, Touré Kane N, Lanièce I, Ndir A, Vergne L, Ndoye I, Mboup S, Sow PS, Delaporte E, . ANRS 1215/1290 Study Group Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr 2005, 1:14-17. ANRS 1215/1290 Study Group.
34. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887-895. 10.1097/00002030-200404090-00006, 15060436.
35. Mujugira A, Wester CW, Kim S, Bussmann H, Gaolathe T. Patients with advanced HIV type 1 infection initiating antiretroviral therapy in Botswana: treatment response and mortality. AIDS Res Hum Retroviruses 2009, 25:127-133. 10.1089/aid.2008.0172, 19239353.
36. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffat H, Essex M, Marlink R. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005, 40:336-343. 10.1097/01.qai.0000159668.80207.5b, 16249709.
37. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, Puertas G, Taburet AM, Ly N, Rouzioux C, Balkan S, Quillet C, Delfraissy JF. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007, 21:2293-2301. 10.1097/QAD.0b013e32828cc8b7, 18090277.
38. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, Diakite N, Karcher S, Grundmann C, Marlink R, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS 2008, 22:873-882. 10.1097/QAD.0b013e3282f768f8, 18427206.
39. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright P, Gulick R, Johnson WD, Pape JW, Fitzgerald DW. Antiretroviral therapy in a thousand patients with AIDS in Haiti. The New England journal of medicine 2005, 353:2325-2334. 10.1056/NEJMoa051908, 16319381.
40. Urassa W, Bakari M, Sandstrom E, Swai A, Pallangyo K, Mbena E, Mhalu F, Biberfeld G. Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS 2004, 18:433-438. 10.1097/00002030-200402200-00009, 15090795.
41. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, . ART Cohort Collaboration Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129. 10.1016/S0140-6736(02)09411-4, 12126821, ART Cohort Collaboration.
42. National-AIDS-Control-Programme-Tanzania National Guidelines for the Clinical Management of HIV and AIDS. Book National Guidelines for the Clinical Management of HIV and AIDS (Editor ed.^eds.). City 2005, National-AIDS-Control-Programme-Tanzania.
43. UNAIDS Financial Resources Required to Achieve Universal Access to HIV Prevention, Treatment, Care and Support. 2006, UNAIDS.